MTOR and hepatocellular carcinoma: To test the role of the KIF2C in mTORC1 signaling and HCC progression, we treated KIF2C-overexpressing and KIF2C-depleted HCC cells with the mTOR agonist MHY1485 and the mTOR inhibitor INK-128, respectively.